Improving Asthma Care Together (IMPACT): A Shared Management Pilot Study

Sponsor
University of Washington (Other)
Overall Status
Recruiting
CT.gov ID
NCT04908384
Collaborator
National Institute of Nursing Research (NINR) (NIH)
60
1
2
17
3.5

Study Details

Study Description

Brief Summary

This study aims to iteratively develop, refine and test the Improving Asthma Care Together (IMPACT) Intervention for school-age children (7-11 years) with persistent asthma and their parents.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Improving Asthma Care Together (IMPACT)
N/A

Detailed Description

Asthma is one of the most common chronic conditions of childhood, affecting over six million US children. Asthma treatment relies on self-management including symptom monitoring and response, trigger avoidance, and timely and appropriate medication use. Unfortunately, fewer than 50% of children with asthma are adherent to asthma treatment regimens, leading to increased disease morbidity and mortality and potentially irreversible airway damage.

Children with asthma are missing a voice in their own care. The school-age years (7-11) represent a natural transition in asthma management, as children must assume some responsibility for asthma-related care while they spend increasing time away from parents at school and other extracurricular activities. Yet, existing interventions focus on parents alone and use prescriptive approaches, telling the parent what to "do" to the child to manage their asthma. As a result, current strategies are failing to provide children with asthma and their families the tools they need to manage asthma successfully within the realities of their daily lives.

Using a Human-Centered Design (HCD) framework, the investigators co-designed a tailored asthma shared management mobile health application that pairs the parent and child together as a team and facilitates the intentional transition of some asthma management to the child. The hypothesis is that by involving children in their own care, participants will improve asthma management in the present, but also establish lifelong successful self-management skills. The objective of the proposed study is to pilot test the Improving Asthma Care Together (IMPACT) mobile health application with parent-child dyads. Based on the preliminary data, the central hypothesis is that IMPACT will be effective for delivering a shared asthma management intervention for children and their parents.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Improving Asthma Care Together (IMPACT): A Shared Management Pilot Study for Children With Asthma and Their Parents
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: IMPACT Intervention

IMPACT health application and wearable device

Behavioral: Improving Asthma Care Together (IMPACT)
IMPACT is a novel health application and wearable device

No Intervention: Usual care control

Usual care control.

Outcome Measures

Primary Outcome Measures

  1. Asthma responsibility questionnaire change from baseline to 8 weeks [8 weeks]

    10- items, 5-point scale to report asthma management task responsibility, higher scores indicate higher asthma management responsibility for child.

  2. Asthma responsibility questionnaire change from 8 to 16 weeks [16 weeks]

    10- items, 5-point scale to report asthma management task responsibility, higher scores indicate higher asthma management responsibility for child.

  3. Asthma management self-efficacy change from baseline to 8 weeks [8 weeks]

    13-items (parent) and 12-items (child), 5-point scale assesses asthma self-efficacy, higher scores indicate higher selfefficacy.

  4. Asthma management self-efficacy change from 8 weeks to 16 weeks [16 weeks]

    13-items (parent) and 12-items (child), 5-point scale assesses asthma self-efficacy, higher scores indicate higher selfefficacy.

Secondary Outcome Measures

  1. Spirometry - FEV1 change from baseline to 8 weeks [8 weeks]

    Spirometry - objective measure of expiratory lung function will be used to evaluate asthma control. Specifically, the FEV1 measure will be used and interpreted according to the national spirometry guideline cutpoints (NAEPP EPR4 report)

  2. Spirometry - FEV1 change from 8 weeks to 16 weeks [16 weeks]

    Spirometry - objective measure of expiratory lung function will be used to evaluate asthma control. Specifically, the FEV1 measure will be used and interpreted according to the national spirometry guideline cutpoints (NAEPP EPR4 report)

  3. Spirometry - FEV1 [Weekly through intervention (weeks 0 through 8)]

    Spirometry - objective measure of expiratory lung function will be used to evaluate asthma control. Intervention group will measure weekly via home spirometry device and IMPACT application. Specifically, the FEV1 measure will be used and interpreted according to the national spirometry guideline cutpoints (NAEPP EPR4 report)

  4. Spirometry - FEV1/FVC change from baseline to 8 weeks [8 weeks]

    Spirometry - objective measure of expiratory lung function will be used to evaluate asthma control. Specifically, the FEV1/FVC measure will be used and interpreted according to the national spirometry guideline cutpoints (NAEPP EPR4 report)

  5. Spirometry - FEV1/FVC change from 8 weeks to 16 weeks [16 weeks]

    Spirometry - objective measure of expiratory lung function will be used to evaluate asthma control. Specifically, the FEV1/FVC measure will be used and interpreted according to the national spirometry guideline cutpoints (NAEPP EPR4 report)

  6. Spirometry - FEV1/FVC [Weekly through intervention (weeks 0 through 8)]

    Spirometry - objective measure of expiratory lung function will be used to evaluate asthma control. Intervention group will measure weekly via home spirometry device and IMPACT application. Specifically, the FEV1/FVC measure will be used and interpreted according to the national spirometry guideline cutpoints (NAEPP EPR4 report)

  7. Childhood Asthma Control Test change from baseline to 8 weeks [8 weeks]

    7 total items--3 parent (5-point scale) and 4 child (3-point scale)-- assess asthma control, higher scores indicate better control

  8. Childhood Asthma Control Test change from 8 weeks to 16 weeks [16 weeks]

    7 total items--3 parent (5-point scale) and 4 child (3-point scale)-- assess asthma control, higher scores indicate better control

  9. Childhood Asthma Quality of Life change from baseline to 8 weeks [8 weeks]

    Self-report child-reported asthma quality of life, with higher scores indicating better quality of life. PROMIS Asthma Impact Scale - 8 items, 5-point scale

  10. Childhood Asthma Quality of Life change from 8 weeks to 16 weeks [16 weeks]

    Self-report child-reported asthma quality of life, with higher scores indicating better quality of life. PROMIS Asthma Impact Scale - 8 items, 5-point scale

  11. Parent Asthma Quality of Life change from baseline to 8 weeks [8 weeks]

    Self-report parent-reported asthma quality of life, with higher scores indicating better quality of life. PROMIS Asthma Impact Scale - 8 items, 5-point scale

  12. Parent Asthma Quality of Life change from 8 weeks to 16 weeks [16 weeks]

    Self-report parent-reported asthma quality of life, with higher scores indicating better quality of life. PROMIS Asthma Impact Scale - 8 items, 5-point scale

  13. Acceptability of intervention measure [8 weeks]

    4 items using 5-point scale; higher scores indicate higher acceptability.

  14. Medication adherence change from baseline to 8 weeks [8 weeks]

    Medication Adherence Report Scale for Asthma, 10-items, 5-point scale assessing reported asthma controller medication adherence. Higher scores indicate better adherence.

  15. Medication adherence change from 8 weeks to 16 weeks [16 weeks]

    Medication Adherence Report Scale for Asthma, 10-items, 5-point scale assessing reported asthma controller medication adherence. Higher scores indicate better adherence.

Eligibility Criteria

Criteria

Ages Eligible for Study:
7 Years to 11 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
CHILD Inclusion Criteria:
  • Clinician diagnosis of persistent asthma (prescription for daily asthma medication)

  • Speak English

PARENT Inclusion Criteria:
  • 18 years or older

  • Child's primary caregiver

  • Able to understand and read English

  • Reside with the child 50% or more

  • Legal guardian who can consent for child to participate

  • Have access to a smart phone and reliable home internet access

CHILD Exclusion Criteria:
  • Parent report of developmental delay (language < 5 year level)

  • Co-morbid cancer, diabetes, ADHD

  • Current asthma exacerbation at the time of recruitment

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Washington School of Nursing Seattle Washington United States 98195

Sponsors and Collaborators

  • University of Washington
  • National Institute of Nursing Research (NINR)

Investigators

  • Principal Investigator: Jennifer T Sonney, PhD, University of Washington

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jennifer Sonney, Assistant Professor, School of Nursing, University of Washington
ClinicalTrials.gov Identifier:
NCT04908384
Other Study ID Numbers:
  • STUDY00010461
  • KL2TR002317
  • 1R21NR019328
First Posted:
Jun 1, 2021
Last Update Posted:
Sep 27, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jennifer Sonney, Assistant Professor, School of Nursing, University of Washington
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2021